NCT02402660View on ClinicalTrials.gov

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions
Stargardt DiseaseStargardt Macular DegenerationStargardt Macular DystrophyAutosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
DRUG

ALK-001

Daily, oral administration for 24 months

DRUG

Placebo

Daily, oral administration for 24 months

Trial Locations (14)

10032

Alkeus Site, New York

11590

Alkeus Site, Westbury

21287

Alkeus Site, Baltimore

32601

Alkeus Site, Gainesville

33136

Alkeus Site, Miami

46202

Alkeus Site, Indianapolis

49546

Alkeus Site, Grand Rapids

53226

Alkeus Site, Milwaukee

77025

Alkeus Site, Houston

80045

Alkeus Site, Aurora

84132

Alkeus Site, Salt Lake City

85020

Alkeus Site, Phoenix

90095

Alkeus Site, Los Angeles

98383

Alkeus Site, Silverdale

Sponsors
All Listed Sponsors
lead

Alkeus Pharmaceuticals, Inc.

INDUSTRY